Castle Biosciences 上调 2026 年营收指引至 3.65 亿-3.75 亿美元，TissueCypher 业务量增长趋势达 50%-52% (NASDAQ:CSTL)
· seekingalpha.com
Castle Biosciences (CSTL) 2026 年第二季度财报电话会议摘要：营收增长 20%，指引上调，TissueCypher 业务剧增，面临利润率/平均售价 (ASP) 风险。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...